Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* A male or female 18 years of age or older at the time of the first vaccination~* Subjects who the investigator believes can and will comply with the requirements of the protocol.~* Written informed consent obtained from the subject.~* Healthy subjects or those with chronic well-controlled disease as established by physical examination before entering into the study.~* Female subjects of non-childbearing potential may be enrolled in the study.~* Female subjects of childbearing potential may be enrolled in the study, if the subject:~* - has practiced adequate contraception for 30 days prior to vaccination,~* - and has a negative urine pregnancy test on the day of vaccination,~* and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series~Exclusion Criteria:~* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the dose of the study vaccine or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within three months prior to enrolment in this study or planned administration during the study period.~* Administration of an influenza vaccine during the 6 months preceding entry into the study.~* Planned administration / administration of a vaccine not foreseen by the study protocol within 30 days before vaccination and up to Day 21.~* Any contra-indication to intramuscular administration of the influenza vaccines.~* History of hypersensitivity/anaphylaxis to a previous dose of influenza vaccine, history of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.~* Any administration of a long-acting immune-modifying drug within 3 months before study start, or planned administration during the study period.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* Acute disease and/or fever at the time of enrolment.~* Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.~* History of Guillain-Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.~* Administration of immunoglobulins and/or any blood products within the three months prior to the enrolment in this study, or planned during the study.~* History of chronic alcohol consumption and/or drug abuse.~* Any condition which, in the opinion of the investigator, prevents the subject from participating in the study~* Pregnant or lactating female.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- GSK2321138A Lot 1 Group (Type: EXPERIMENTAL): Subjects received one dose of the GSK2321138A vaccine, Lot 1, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
- GSK2321138A Lot 2 Group (Type: EXPERIMENTAL): Subjects received one dose of the GSK2321138A vaccine, Lot 2, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
- GSK2321138A Lot 3 Group (Type: EXPERIMENTAL): Subjects received one dose of the GSK2321138A vaccine, Lot 3, at Day 0. The GSK2321138A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
- Fluarix Group (Type: ACTIVE_COMPARATOR): Subjects received one dose of the Fluarix™ vaccine at Day 0. The Fluarix™ vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.
- GSK2604409A Group (Type: ACTIVE_COMPARATOR): Subjects received one dose of the GSK2604409A vaccine at Day 0. The GSK2604409A vaccine was administered as a single dose intramuscularly in the deltoid region of the non-dominant arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete